Bryce A Binstadt

Emailbinstadtumnedu

Research activity per year

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

SDG 2 Zero Hunger
SDG 3 Good Health and Well-being
SDG 4 Quality Education
SDG 10 Reduced Inequalities
SDG 15 Life on Land

Fingerprint

The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

1 Similar Profiles

9 Active
39 Finished

Functions of LynA and LynB kinases in myeloid-cell pro-inflammatory signaling and lupus
Freedman, T. (PI), Binstadt, B. A. (CoI) & Lipscomb, M. W. (CoI)
NIH NIAMS NATIONALL INSTITUTE OF ARTHRIT
9/1/25 → 8/31/30
Project: Research project
Stromal-immune cell crosstalk promotes autoimmune valvular carditis
Binstadt, B. A. (PI)
NIH NATIONAL INST OF ALLERGY & INFECT DI
11/14/24 → 10/31/26
Project: Research project
A Phase 3, Open label, Uncontrolled Single-arm Study to Evaluate the Efficacy, Pharmacokinetics, andSafety of Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen inChildren from 6 Years to less than 18 Years o
Binstadt, B. A. (PI)
AMGEN INC
3/1/24 → 3/31/34
Project: Research project
Open-label, randomized, assessor-blinded, efficacy, safety, tolerability, and pharmacokinetics study of subcutaneous risankizumab with an adalimumab reference arm in children with active juvenile psoriatic arthritis (Study M23-732)
Binstadt, B. A. (PI)
ABBVIE INC
10/11/23 → 10/31/33
Project: Research project
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to evaluate thePharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV anifrolumab in Pediatric Participants 5 to< 18 Years of Age with Moderate toSevere
Binstadt, B. A. (PI)
ASTRAZENECA
7/27/23 → 7/30/33
Project: Research project

95 Article
13 Review article
4 Meeting Abstract
1 Chapter
More
- 1 Editorial

Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease Cohort
CARRA Registry investigators, CARRA FROST Investigators & the CARRA Registry SJIA-LD Cohort Investigators, 2026, (Accepted/In press) In: Arthritis Care and Research.
Research output: Contribution to journal › Article › peer-review
1 Link opens in a new tab Scopus citations
Disease activity at two consecutive registry visits and subsequent medication escalation for patients with juvenile idiopathic arthritis in the CARRA registry
For the CARRA Registry Investigators, Dec 2025, In: Pediatric Rheumatology. 23, 1, 77.
Research output: Contribution to journal › Article › peer-review

Open Access
Effect of an Electronic Pill Bottle on Hydroxychloroquine Adherence in Pediatric Lupus: Results of a Novel Direct-to-Family Pilot Trial
with the CARRA Registry investigators, Jan 2025, In: ACR Open Rheumatology. 7, 1, e11780.
Research output: Contribution to journal › Article › peer-review

Open Access
Female Mice Lacking LSD1 in Myeloid Cells Are Resistant to Inflammatory Bone Loss
Astleford-Hopper, K., Saavedra, F., Bittner-Eddy, P., Stein, C., Auger, J., Clark, R., Abrahante Llorens, J. E., Binstadt, B. A., Thumbigere-Math, V. & Mansky, K. C., Jul 2025, In: Cells. 14, 14, 1111.
Research output: Contribution to journal › Article › peer-review

Open Access
Long-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry
For the CARRA Registry Investigators, Dec 2025, In: Pediatric Rheumatology. 23, 1, 105.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Link opens in a new tab Scopus citations

Bryce A Binstadt

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

Functions of LynA and LynB kinases in myeloid-cell pro-inflammatory signaling and lupus

Stromal-immune cell crosstalk promotes autoimmune valvular carditis

A Phase 3, Open label, Uncontrolled Single-arm Study to Evaluate the Efficacy, Pharmacokinetics, andSafety of Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen inChildren from 6 Years to less than 18 Years o

Open-label, randomized, assessor-blinded, efficacy, safety, tolerability, and pharmacokinetics study of subcutaneous risankizumab with an adalimumab reference arm in children with active juvenile psoriatic arthritis (Study M23-732)

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to evaluate thePharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV anifrolumab in Pediatric Participants 5 to< 18 Years of Age with Moderate toSevere

Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease Cohort

Disease activity at two consecutive registry visits and subsequent medication escalation for patients with juvenile idiopathic arthritis in the CARRA registry

Effect of an Electronic Pill Bottle on Hydroxychloroquine Adherence in Pediatric Lupus: Results of a Novel Direct-to-Family Pilot Trial

Female Mice Lacking LSD1 in Myeloid Cells Are Resistant to Inflammatory Bone Loss

Long-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry

Bryce A Binstadt

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Collaborations and top research areas from the last five years

Projects

Research output